Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genentech Invests $700M in New Manufacturing Facility in Holly Springs, NC | Contract Pharma

What are you searching for?

Sign in
Breaking News

Genentech Invests $700M in New Manufacturing Facility in Holly Springs, NC

The project will add more than 400 high-wage manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Genentech, a member of the Roche Group, has announced plans to invest more than $700 million in a new 700,000 square foot drug manufacturing facility in Holly Springs, NC.

The project will add more than 400 high-wage manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development. The new facility will ultimately support Roche and Genentech’s future portfolio of next-generation obesity medicines, and this initial investment could expand in the future based on business needs and the U.S. policy environment.

Roche and Genentech’s current U.S. footprint includes 13 manufacturing and 15 R&D sites across the company’s Pharmaceutical and Diagnostics Divisions and 25,000 employees in 24 sites across eight U.S. states.

Genentech CEO, Ashley Magargee, said, “Our new facility near Raleigh, North Carolina, an established biopharmaceutical talent hub, will serve as an important new setting within our manufacturing network to help deliver on the promise of our company’s life-changing science and industry-leading pipeline.”

Together, Roche and Genentech are investing in the infrastructure, talent, and technologies needed to deliver the next generation of medical breakthroughs. In April, Roche announced plans to invest $50 billion into the United States in the next five years, further strengthening its already significant U.S. footprint.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics